Status:
COMPLETED
Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine
Lead Sponsor:
New Valley University
Conditions:
Greater Occipital Nerve Block
Sphenopalatine Ganglion Block
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with epis...
Detailed Description
Migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. Peripheral nerve blocks such as Greater Occipital Nerve (GON) and Sphenopalatine Ganglion...
Eligibility Criteria
Inclusion
- Adults aged 18-65 years.
- Both sexes.
- Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Failure to achieve adequate relief with at least one prophylactic migraine treatment.
Exclusion
- Chronic migraine (≥15 headache days per month).
- History of nerve blocks within the last 6 months.
- Known allergy to anesthetic agents.
- Pregnancy or lactation.
- Active psychiatric conditions affecting compliance.
Key Trial Info
Start Date :
May 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 3 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06997562
Start Date
May 1 2024
End Date
May 3 2025
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Valley University
New Valley, New Valley Governorate, Egypt, 72511